Sponsor content

Harnessing the power of natural killer cells for cancer immunotherapy

By leveraging its unique and versatile production-platform technology, Glycostem has developed highly pure and active cancer-fighting cell therapy products that are safe and effective for allogeneic transplantation in patients with hematological cancers and solid tumors.

Go to the profile of Glycostem
Aug 21, 2017
1
0
Like 1 Comment

Download the Full PDF

Natural killer (NK) cells are critical immune cells in the fight against cancer and have recently been explored as a promising therapeutic alternative to T-cell-based approaches. In particular, NK cells play a critical role in eliminating circulating cancer stem cells with high metastatic potential. Moreover, engineered NK cells are considered less risky for patients than their T cell counterparts because NK cells have never been thought to cause graft-versus-host disease. NK cells are cleared from circulation more rapidly after mediating their anticancer effects and unlike chimeric antigen receptor expressing T cells, are less likely to produce potentially fatal cytokines, besides providing a failsafe mechanism when cytotoxic T cells are unable to recognize tumors. Because NK cells are highly dysfunctional and reduced in number in can­cer patients compared with those in healthy individu­als, the transfer of large numbers of NK cells represent a promising therapeutic strategy.

However, transplantation studies in which autolo­gous NK cells are removed, expanded to large num­bers ex vivo, and transferred back into the patient, have not demonstrated significant clinical ben­efit because of the problem of self-tolerance, which allows tumor cells to escape immunological control mechanisms. In addition, autologous cell transplanta­tion is not off-the-shelf and is associated with limited expansion, poor anticancer efficacy and high costs. Because of these limitations, development efforts have focused on safe and effective allogeneic NK cell transfusion procedures, in which a patient receives cells from a genetically unrelated donor.

Glycostem is a clinical-stage company on a mission to harness the power of allogeneic cell products in the field of cellular immunotherapy. The European-based biotech company, which was founded in 2007, recently tested its lead candidate oNKord for safety in a phase 1 study in subjects with acute myeloid leukemia. oNKord, which comprises highly pure and cytolytic NK cells generated ex vivo from umbilical cord blood progenitor cells, did not cause toxicity or graft-versus-host disease, further expanded and matured in vivo, migrated to the bone marrow, and killed leu­kemic blasts. Initial observations after treatment with a single dose of oNKord suggest that one could expect a strong reduction of residual disease as well as pro­longed progression-free survival and overall survival.

This revolutionary NK-cell-based therapy has been granted Orphan Drug Designation by the US Food and Drug Administration and the European Medicines Agency for the treatment of acute myeloid leukemia, and conditional product approval is expected in Europe in 2020 or 2021. Further, oNKord also has the potential to treat multiple myeloma and other hematological cancers, as well as solid tumors such as colorectal cancer, cervical cancer, epider­moid cancer, head and neck cancer, lung cancer, and breast cancer. After the successful completion of the phase 1 clinical trial, Glycostem began to set up automated, closed-system good manufacturing practice (GMP)-certified manufacturing facilities to initiate multi-center clinical trials for acute myeloid leukemia, multiple myeloma, and solid tumors.

“At Glycostem, we believe that natural killer cells will become the new star in the domain of cellular immunotherapy,” said the company’s chairman and CEO, Troels Jordansen. “By developing a suite of inno­vative natural killer cell products, we are setting the stage to make a considerable impact on the future treatment of cancer.”

Versatile platform technology

Glycostem is opening new horizons in allogeneic NK-cell-based immunotherapy, thanks in large part to its cutting-edge platform technology. In recent years, Glycostem’s platform technology has enabled a closed-system cell-culture process for the large-scale expansion of CD34+ hematopoietic stem and progenitor cells, derived mainly from umbilical cord blood. Umbilical cord blood is advantageous because it is a rich source of stem cells, its use is not restricted by ethical considerations, and it is commercially avail­able for large-scale use at excellent quality, reliability, and cost (Fig. 1).

Glycostem’s state-of-the-art platform technology, which uses a proprietary, fully synthetic cell-culture medium and a patented combination of growth factors, allows further differentiation of these hematopoietic stem and progenitor cells into fully functional immune cells, including NK cells and antigen-presenting cells such as dendritic cells.

Figure 1: Closed-system cell-culture production process.

“Over the last 10 years, Glycostem has established a reproducible and efficient closed-production pro­cess protected by six patent families,” Jordansen said. “This makes Glycostem the leading cellular immuno­therapy company focused on developing a safe and cost-effective allogeneic approach with the promise of providing the first truly off-the-shelf products.”

Glycostem’s unique, versatile production-technology platform is able to create a multitude of off-the-shelf products to treat various types of cancer. Moreover, Glycostem is developing second-generation products with dedicated functionality, such as gene-modified NK cells, and NK cells engineered to express chimeric antigen receptors that target specific tumor antigens.

Currently, Glycostem is initiating additional partner­ships to further explore the potential of combining their NK cell products with antibodies, small mol­ecules, or chemotherapy to enhance therapeutic responses against cancers. “There are growing oppor­tunities to augment the cancer-fighting capabilities of NK cells,” Jordansen said. “Through future collabora­tions with academic and industrial partners offering innovative technologies, we hope to spearhead the development of novel therapeutic strategies that will maximize the anticancer effects of natural killer cells.”

Contact:

Troels Jordansen,
CEO/Chairman
Glycostem Therapeutics
Oss, the Netherlands
Tel: +31 412 211 001
Email: troels@glycostem.com
Website: www.glycostem.com

Go to the profile of Glycostem

Glycostem

Glycostem has developed a platform technology for the expansion and differentiation of allogeneic hematopoietic stem and progenitor cells derived from various sources like umbilical cord blood (UCB), bone marrow (BM) or mobilized peripheral blood (mPB). Within the last years, Glycostem's platform technology enables a closed system cell culture process for the expansion of CD34+ hematopoietic stem and progenitor cells and further differentiation into fully functional immune cells, i.e. Natural Killer (NK) cells or antigen presenting cells such as dendritic cells. The technology platform is based on the use of closed bioreactor systems in combination with a proprietary synthetic cell culture medium (GBGM - Glycostem Basal Growth Medium) and a patented combination of growth factors. Glycostem has treated 10 elderly and fragile AML patients in a phase I setting with excellent safety profile and strong indication of clinical efficacy. Year 1 survival data showed 80% compared to population data showing 35%. By late 2019 Glycostem expects to have GMP approved facilities utilising closed system technology resulting is the lowest possible production cost with off the shelf products for our pivotal clinical trial starting early 2020.

No comments yet.